Bristol Myers Squibb reports positive ACTION-1 results
Published on 10/17/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSACTION-1 trial update
- Bristol Myers Squibb announced positive ACTION-1 interim results on October 12, 2026.
- ACTION-1 is a Phase 3 trial evaluating RYZ101 in GEP-NETs.
- The study's identifier is NCT05477576.
Bristol Myers Squibb announced positive topline results from the planned interim analysis of the Phase 3 ACTION-1 trial on October 12, 2026, according to the company's Bristol Myers Squibb release. The company said the study met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival.
Market context: Market report S&P 500.
The week in figures
ACTION-1 is a randomized Phase 3 trial identified as NCT05477576. It evaluates RYZ101, also known as 225Ac-DOTATATE, against investigator's choice of standard of care in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors who progressed following lutetium-177-based therapy. These details are from the company's October 12, 2026 release.
Chronology of the week
On October 12, 2026, Bristol Myers Squibb reported that the interim ACTION-1 analysis met its primary endpoint. The release identified RayzeBio, Inc., a Bristol Myers Squibb company, as the trial's conducting organization and said safety results were consistent with the known RYZ101 safety profile. Bristol Myers Squibb said detailed results are expected at a future medical meeting.
Dates of the coming week
The fetched company release does not identify a dated company event in the coming week.
Weekend trading
The next price is shown from the start of trading by the continuously updated real-time quote of Bristol Myers Squibb stock.
